Related Experiment Video
Updated: Aug 9, 2026

09:42
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
Published on: January 2, 2017
Human antibodies as next generation therapeutics
M A van Dijk1, J G van de Winkel
1Genmab, Dept Immunology, University Medical Center Utrecht, PO Box 85090, 3508 GA Utrecht, The Netherlands. M.A.vandijk@med.uu.nl
Current Opinion in Chemical Biology
|July 27, 2001
Summary
Therapeutic monoclonal antibodies often contain mouse proteins, risking patient complications. New technologies now enable the development of fully human antibodies, improving safety and efficacy in antibody therapeutics.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Background:
- Antibodies and derivatives represent 25% of therapeutics in development.
- Approved monoclonal antibodies contain mouse sequences, posing risks of allergic reactions.
- Partially murine antibodies can cause adverse effects in human patients.
Purpose of the Study:
- To highlight the limitations of current murine-based antibody therapeutics.
- To introduce the development and benefits of fully human antibodies.
- To discuss technologies enabling the creation of 100% human antibodies.
Main Methods:
- Review of existing antibody development technologies.
- Analysis of regulatory approvals for monoclonal antibodies.
- Assessment of immunogenicity associated with murine protein sequences.
Main Results:
- All currently approved therapeutic monoclonal antibodies contain mouse protein sequences.
- Partially murine antibodies have the potential to cause allergic complications.
- Technologies for developing fully human antibodies are advancing rapidly.
Conclusions:
- Fully human antibodies are becoming the standard for therapeutic development.
- Reducing or eliminating murine components enhances antibody safety.
- Advancements in technology facilitate the creation of 100% human antibodies.
Related Concept Videos
Humoral Immune Responses
Overview
Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Cross-reactivity
Overview
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Structure and Classes
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

